Dianthus Therapeutics, Inc. (DNTH)
DNTHNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$86.70
-3.30 (-3.67%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $5.00bn
- P/E
- –
- EPS, last 4 quarters
- $-3.99
- Dividend yield
- –
- Day range
- –
- 52-week range
- $34.29 to $117.88
- Average volume
- 893.4k
- Previous close
- $90.00
Analysts
10 coveringBuy10 buy, 0 hold, 0 sell
Targets a year out average $141.89, +63.7% from here
Earnings
next estimate $-0.9600Next report
Dec 2025
-45.9%
Mar 2026
+27.4%
Jun 2026
+3.2%
Sep 2026
+19.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $284.0k | $463.0k | $761.0k | $1.21m |
| Gross profit | $284.0k | $463.0k | $761.0k | $1.21m |
| Operating income | -$69.54m | -$46.53m | -$61.48m | -$58.47m |
| Net income | -$64.43m | -$40.83m | -$50.22m | -$46.64m |
Last four quarters: revenue $2.72m, margin -7436.5%, free cash flow -$175.85m
News
8 latest- Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?Zacks · 1 day ago
- Dianthus Therapeutics, Inc. Reports Q3 2026 Financial Results and Highlights Clinical ProgressFintel · 6 days ago
- Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Regeneron (REGN) Q3 Earnings and Revenues Beat EstimatesZacks · Oct 30, 2026
- Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthZacks · Oct 29, 2026
- Dianthus Therapeutics Enters Oversold Territory (DNTH)BNK Invest · Oct 22, 2026
- Citigroup Initiates Coverage of Dianthus Therapeutics with Buy RatingFintel · Sep 5, 2026
- Dianthus Therapeutics Grants Inducement Awards To Four New Employees RTTNews · Sep 3, 2026
The company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- dianthustx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.